These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24311781)

  • 1. Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.
    Cattaneo M; Baronchelli S; Schiffer D; Mellai M; Caldera V; Saccani GJ; Dalpra L; Daga A; Orlandi R; DeBlasio P; Biunno I
    J Biol Chem; 2014 Jan; 289(5):2826-38. PubMed ID: 24311781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of endoplasmic reticulum (ER) stress in gliomas.
    Markouli M; Strepkos D; Papavassiliou AG; Piperi C
    Pharmacol Res; 2020 Jul; 157():104823. PubMed ID: 32305494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic targeting of glioma stem cells: Short-term and long-term treatments with valproic acid modulate DNA methylation and differentiation behavior, but not temozolomide sensitivity.
    Riva G; Butta V; Cilibrasi C; Baronchelli S; Redaelli S; Dalprà L; Lavitrano M; Bentivegna A
    Oncol Rep; 2016 May; 35(5):2811-24. PubMed ID: 26986767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition.
    Yoo YD; Lee DH; Cha-Molstad H; Kim H; Mun SR; Ji C; Park SH; Sung KS; Choi SA; Hwang J; Park DM; Kim SK; Park KJ; Kang SH; Oh SC; Ciechanover A; Lee YJ; Kim BY; Kwon YT
    EMBO Rep; 2017 Jan; 18(1):150-168. PubMed ID: 27993939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability.
    Sheikh S; Saxena D; Tian X; Amirshaghaghi A; Tsourkas A; Brem S; Dorsey JF
    Mol Cancer Res; 2019 May; 17(5):1102-1114. PubMed ID: 30642878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway.
    Sareddy GR; Viswanadhapalli S; Surapaneni P; Suzuki T; Brenner A; Vadlamudi RK
    Oncogene; 2017 Apr; 36(17):2423-2434. PubMed ID: 27893719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance.
    Ko CY; Lin CH; Chuang JY; Chang WC; Hsu TI
    Mol Neurobiol; 2018 Apr; 55(4):3211-3223. PubMed ID: 28478507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
    Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
    Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproic Acid Sensitizes Glioma Cells to Luteolin Through Induction of Apoptosis and Autophagy via Akt Signaling.
    Han W; Yu F; Wang R; Guan W; Zhi F
    Cell Mol Neurobiol; 2021 Nov; 41(8):1625-1634. PubMed ID: 32719967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-30a suppresses self-renewal and tumorigenicity of glioma stem cells by blocking the NT5E-dependent Akt signaling pathway.
    Peng L; Ming Y; Zhang L; Zhou J; Xiang W; Zeng S; He H; Chen L
    FASEB J; 2020 Apr; 34(4):5128-5143. PubMed ID: 32067282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.
    Das CM; Aguilera D; Vasquez H; Prasad P; Zhang M; Wolff JE; Gopalakrishnan V
    J Neurooncol; 2007 Nov; 85(2):159-70. PubMed ID: 17534580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
    Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
    J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of the unfolded protein response drives enhanced metabolism and chemoresistance in glioma cells.
    Epple LM; Dodd RD; Merz AL; Dechkovskaia AM; Herring M; Winston BA; Lencioni AM; Russell RL; Madsen H; Nega M; Dusto NL; White J; Bigner DD; Nicchitta CV; Serkova NJ; Graner MW
    PLoS One; 2013; 8(8):e73267. PubMed ID: 24039668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new 2-pyrone derivative, 5-bromo-3-(3-hydroxyprop-1-ynyl)-2H-pyran-2-one, suppresses stemness in glioma stem-like cells.
    Kim RK; Kim MJ; Yoon CH; Lim EJ; Yoo KC; Lee GH; Kim YH; Kim H; Jin YB; Lee YJ; Cho CG; Oh YS; Gye MC; Suh Y; Lee SJ
    Mol Pharmacol; 2012 Sep; 82(3):400-7. PubMed ID: 22648970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NFAT1-Mediated Regulation of NDEL1 Promotes Growth and Invasion of Glioma Stem-like Cells.
    Jiang Y; Song Y; Wang R; Hu T; Zhang D; Wang Z; Tie X; Wang M; Han S
    Cancer Res; 2019 May; 79(10):2593-2603. PubMed ID: 30940662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells.
    Aztopal N; Erkisa M; Erturk E; Ulukaya E; Tokullugil AH; Ari F
    Chem Biol Interact; 2018 Jan; 280():51-58. PubMed ID: 29225137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suberoylanilide hydroxamic acid represses glioma stem-like cells.
    Hsu CC; Chang WC; Hsu TI; Liu JJ; Yeh SH; Wang JY; Liou JP; Ko CY; Chang KY; Chuang JY
    J Biomed Sci; 2016 Nov; 23(1):81. PubMed ID: 27863490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma.
    Luwor R; Morokoff AP; Amiridis S; D'Abaco G; Paradiso L; Stylli SS; Nguyen HPT; Tarleton M; Young KA; O'Brien TJ; Robinson PJ; Chircop M; McCluskey A; Jones NC
    Cancer Invest; 2019; 37(3):144-155. PubMed ID: 30907150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.